Effects of Transarterial Chemoembolization vs Systemic Chemotherapy on the Resectability and Long-term Prognosis of Hepatoblastoma: A Randomized Clinical Trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036005

Enrollment

Unknown

Registered

2020-08-21

Start date

2022-09-30

Completion date

Unknown

Last updated

2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatoblastoma

Interventions

Group 2:Transarterial chemoembolization

Group 1:Systemic chemotherapy

Eligibility

Sex/Gender

All

Age

No minimum to 14 Years

Inclusion criteria

Inclusion criteria: 1. Aged 50x10^9/L, prothrombin time prolonged < 5 seconds.

Exclusion criteria

Exclusion criteria: 1. Refuse to participate in this clinical trial; 2. PRETEXT I stage; 3. The tumor ruptures and hemorrhages; 4. History of other tumors within 5 years; 5. Patients with other serious congenital diseases or poor general conditions; 6. Other diseases that require surgical treatment; 7. Cannot or refuse to comply with the treatment and monitoring requirements of this study; 8. Participating in other clinical trials.

Design outcomes

Primary

Measure	Time frame
Time to resection;	—

Secondary

Measure	Time frame
Perioperative complication rate;Progression-free survival;Overall survival;	—

Countries

China

Contacts

Public ContactGuanghua Liu

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

liuguanghua@xinhuamed.com.cn+86 13681726929

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026